Navitoclax (ABT-263)

Name: Navitoclax (ABT-263)
Brand: Selleck Chemicals
SKU: S1001
Rating: 5 (221 reviews)

For research use only.

Catalog No.S1001

221 publications

CAS No. 923564-51-6

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Selleck's Navitoclax (ABT-263) has been cited by 221 publications

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Metab, 2019, 30(1):129-142

PubMed: 31155496 ( click the link to review the publication )

Cancer Discov, 2018, 8(12):1598-1613

PubMed: 30254092 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(2):112-117

PubMed: 29200207 ( click the link to review the publication )

Cancer Cell, 2017, 32(4):490-505.e10

PubMed: 29017059 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Nat Cell Biol, 2020, 4

PubMed: 32367049 ( click the link to review the publication )

Sci Transl Med, 2020, 15;12(539) pii: eaax3799

PubMed: 32295900 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

Nat Commun, 2020, 11(1):752

PubMed: 32029722 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Blood Cancer J, 2020, 10(6):72

PubMed: 32591499 ( click the link to review the publication )

Aging Cell, 2020, 19(4):e13133

PubMed: 32175667 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )
J Med Chem, 2020, 63(22):13733-13744

PubMed: 33197310 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2551

PubMed: 32911681 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):130

PubMed: 33239070 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):854

PubMed: 33056980 ( click the link to review the publication )

Cell Death Dis, 2020, 8;11(6):443

PubMed: 32513939 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3793-3801

PubMed: 32687646 ( click the link to review the publication )

Antioxidants (Basel), 2020, 9(11)E1143

PubMed: 33218059 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.0586.2020

PubMed: 33288732 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 14(3):e0008150

PubMed: 32196500 ( click the link to review the publication )

Sci Rep, 2020, 14;10(1):222

PubMed: 31937836 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 4;526(3):612-617

PubMed: 32247610 ( click the link to review the publication )

Laryngoscope, 2020, 10.1002

PubMed: 31894587 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(6):4849-4856

PubMed: 32424523 ( click the link to review the publication )

Biomater Sci, 2020, 8(8):2264-2273

PubMed: 32134074 ( click the link to review the publication )

Cancer Lett, 2020, S0304-3835(20)30635-2

PubMed: 33259900 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0234103

PubMed: 32645016 ( click the link to review the publication )

Leuk Lymphoma, 2020, 1-5

PubMed: 32627634 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):95

PubMed: 32677976 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )
Cancers (Basel), 2020, 12(8):E2137

PubMed: 32752193 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2298

PubMed: 32824203 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, 15;106(4):867-877

PubMed: 31786278 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107897

PubMed: 32668248 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(12):e12391

PubMed: 33231937 ( click the link to review the publication )

Trop Life Sci Res, 2020, 31(3):1-13

PubMed: 33214852 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107830

PubMed: 32610131 ( click the link to review the publication )

Free Radic Biol Med, 2020, 152:227-234

PubMed: 32217194 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.201900218R

PubMed: 32619061 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Sci Adv, 2019, 5(7):eaau9433

PubMed: 31392262 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30860026 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

J Med Chem, 2019, 62(15):6913-6924

PubMed: 31339316 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201900815RR

PubMed: 31408372 ( click the link to review the publication )
Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31801186 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):875-886

PubMed: 30482844 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:218

PubMed: 31462891 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:222

PubMed: 31467488 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2019, 10.1016/j.pdpdt.2019.08.016

PubMed: 31430575 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Nat Metab, 2019, 1(11):1074-1088

PubMed: 31799499 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

J Allergy Clin Immunol, 2018, 142(5):1647-1650.e3

PubMed: 30048671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):215

PubMed: 29335437 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Oncogene, 2018, 37(22):2936-2952

PubMed: 29520102 ( click the link to review the publication )
Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):713

PubMed: 29915306 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(3):1123-1138

PubMed: 30041196 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Cell Cycle, 2018, 17(17):2175-2186

PubMed: 30198376 ( click the link to review the publication )

Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )

Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1940

PubMed: 29208897 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )
Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3655-3675

PubMed: 28877995 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Aging Cell, 2017, 16(4):693-703

PubMed: 28401730 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )

Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )

Cell Discov, 2017, 3:16048

PubMed: 28101374 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

Nat Microbiol, 2016, 1:15034

PubMed: 27572165 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Int J Cancer, 2016, 138(2):507-14

PubMed: 26260669 ( click the link to review the publication )

Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(11):2915-2926

PubMed: 27913811 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):394-402

PubMed: 26694174 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164250

PubMed: 27723829 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )

J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )

Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Oncotarget, 2016, 7(1):845-59

PubMed: 26625317 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Oncotarget, 2016, 7(23):34453-71

PubMed: 27144341 ( click the link to review the publication )

EMBO Rep, 2015, 16(5):618-27

PubMed: 25739811 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Int J Cancer, 2015, 137(12):2959-70

PubMed: 26096065 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )
Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116998

PubMed: 25615615 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):829-834

PubMed: 26622578 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26008975 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27388-402

PubMed: 26317541 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21557-71

PubMed: 26188358 ( click the link to review the publication )

Oncotarget, 2015, 6(17):15551-65

PubMed: 26036632 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26059440 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36456-71

PubMed: 26474387 ( click the link to review the publication )

Sci Rep, 2015, 5:16406

PubMed: 26553339 ( click the link to review the publication )

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )
PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Haematologica, 2013,

PubMed: 23850807 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64051

PubMed: 23691145 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 434(3):695-700

PubMed: 23602897 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )
Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(12):3956-68

PubMed: 21652541 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Targets

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. ^[1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. ^[1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. ^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
FL5.12	NXXRNI1wS3m2b4TvfIlkcXS7IHHzd4F6	MonlNlQhcA>?	NX21fGI2TUN3MDC9JFAvODB2MjFOwG0>	NX36ZolTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4OFE5QDJpPkG4PFQyQDh{PD;hQi=>
FL5.12	NVHHelJpS3m2b4TvfIlkcXS7IHHzd4F6	NHrpXoMzPCCq	MoX2SWM2OCB;IECuNFA2QSEQvF2=	NVPEfllNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4OFE5QDJpPkG4PFQyQDh{PD;hQi=>
RS4:11	NH64b2JCeG:ydH;zbZMh[XO\|YYm=	Mmm5OkBp	MofhSWM2OCB;IECuNFE1KM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6MUW2O{c,OjR6OEG1Olc9N2F-
FDC-P1	MlTTRmNNNTJiaX7obYJqfGmxbjDhd5NigQ>?	NGnVfZgzPCCq	NWDBeoMxUUN3MDC9JFAvODF3IN88US=>	MkH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OEG1OlcoRjJ2OEixOVY4RC:jPh?=
NCI-H1963	MYHDfZRwfG:6aXPpeJkh[XO\|YYm=	MUK0JIRigXN?	M3XvfmlEPTBiPTCwMlAzPjZizszN	NGfMR\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0PFI6QCd-MkO0OFgzQTh:L3G+
NCI-H187	NXSwUJhJS3m2b4TvfIlkcXS7IHHzd4F6	MUK0JIRigXN?	Ml\VTWM2OCB;IECuNFM5PCEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR2OEK5PEc,OjN2NEiyPVg9N2F-
NCI-H1417	MmfQR5l1d3SxeHnjbZR6KGG\|c3H5	NYfDT2hIPCCmYYnz	MnHhTWM2OCB;IECuNFU1OiEQvF2=	MoKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEiyPVgoRjJ\|NES4Nlk5RC:jPh?=
FDC-P1	M2C0N2JEVC26TDDpcohq[mm2aX;uJIF{e2G7	NGixcVEzPCCq	M36ycGlEPTBiPTCwMlA3KM7:TR?=	NUnndYpxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFE2PjdpPkK0PFgyPTZ5PD;hQi=>
NCI-H146	NVXuUYNqS3m2b4TvfIlkcXS7IHHzd4F6	MXe0PEBp	M2Czc2VEPTBiPTCwMlA5PjdizszN	NXPvd2NQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4OFE5QDJpPkG4PFQyQDh{PD;hQi=>
RS4:11	MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MWDFR\|UxKD1iMD6xNVIh\|ryP	NH70WlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmyOlI1Pyd-Mki5NlYzPDd:L3G+
MOLT4	M{\2WGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MW\FR\|UxKD1iMD6zNFMh\|ryP	NF3ZRWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmyOlI1Pyd-Mki5NlYzPDd:L3G+
EoL-1-cell	NGfONXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MojQTWM2OD1yLkCwOlY6KM7:TR?=	NU\IdpU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MV-4-11	M4rTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mmi3TWM2OD1yLkCxOVg3KM7:TR?=	MmH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NKM-1	NVnSSVh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGHVdVVKSzVyPUCuNFE3QTlizszN	NIrZPJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ML-2	NIHMfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXfJR\|UxRTBwMEG5PFMh\|ryP	NF;HVI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
BV-173	MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWjJR\|UxRTBwMEKzNVQh\|ryP	M3fSXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
RS4-11	NHv6VWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWrJR\|UxRTBwMEK1PFch\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HL-60	NVvDeJF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4HWTmlEPTB;MD6wNlkxQCEQvF2=	NFTOWGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KY821	M2HrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlnkTWM2OD1yLkCyPVc2KM7:TR?=	M1zvWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ECC10	NXfuUlJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVHJR\|UxRTBwMEO3PVIh\|ryP	NH:wfG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H720	NXO5V\|M4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3;3W2lEPTB;MD6wOFAyOSEQvF2=	M4TVfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
QIMR-WIL	NXrUXJpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX\JR\|UxRTBwMESyPFch\|ryP	M{\UO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KG-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{fMTWlEPTB;MD6wOFQ5PiEQvF2=	Mo[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TGW	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoHCTWM2OD1yLkC0OlM{KM7:TR?=	NGT2Rlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ATN-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFi2UYtKSzVyPUCuNFQ4OzNizszN	M3jabFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
RH-18	M3G0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV20cFhMUUN3ME2wMlA3ODR6IN88US=>	M3niRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
EW-18	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4XZSmlEPTB;MD6wOlg1OSEQvF2=	M132XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NB17	Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MX7JR\|UxRTBwMEexNlQh\|ryP	M1P5TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SK-NEP-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1noXmlEPTB;MD6wO\|IyOyEQvF2=	NXrlPWZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
P12-ICHIKAWA	NH3rOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYrQVVdnUUN3ME2wMlA4Pzd6IN88US=>	MljUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KARPAS-45	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mm\qTWM2OD1yLkC3PFE2KM7:TR?=	M3LuPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
EW-3	M3mz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEPBfmRKSzVyPUCuNFgxPTNizszN	NHnSToc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NB13	NFv5SpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4mzcmlEPTB;MD6wPFIxOyEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H209	NVK2U5F1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{OwNGlEPTB;MD6wPFcxPCEQvF2=	M3nCUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1092	M1jyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEXWcnVKSzVyPUCuNVAzPzVizszN	NVnMcGpqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NH-12	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4jGTWlEPTB;MD6xNFc1PCEQvF2=	NHn6S5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
697	NFrkVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXjJR\|UxRTBwMUC4N\|kh\|ryP	MorIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KE-37	NIjM[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn7uTWM2OD1yLkGxN\|ch\|ryP	NHLmfG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MOLT-4	NHKzem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmD1TWM2OD1yLkG1NVY6KM7:TR?=	NG\Ieow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CHP-134	MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MW\JR\|UxRTBwMU[zNFYh\|ryP	MnHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
D-283MED	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWjPVYpkUUN3ME2wMlE4Pjh4IN88US=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
LU-135	NFjXbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVTJR\|UxRTBwMUi1OVIh\|ryP	NFP3To49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LU-134-A	M1jicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3K1cmlEPTB;MD6xPFY4OSEQvF2=	MkK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EM-2	NYDnVmdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVLzdVNKUUN3ME2wMlE6QTF6IN88US=>	M1\XUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LU-139	M{\Jcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYjJR\|UxRTBwMkC0PVgh\|ryP	NH7MW5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ALL-PO	NEWzOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYHwdY46UUN3ME2wMlIyQTh6IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB12	NHzwR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH2wd3NKSzVyPUCuNlMyOTVizszN	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KP-N-YN	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVrJR\|UxRTBwMkO1O\|Mh\|ryP	NUDEc4J5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BEN	NWnqbpdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWn6UHdbUUN3ME2wMlI{QTZ6IN88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HCC1569	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4D1UGlEPTB;MD6yOVExPiEQvF2=	NHvv[JA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HuO9	NV3tfGRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWC4VllXUUN3ME2wMlI3PzF3IN88US=>	NHf0XXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
WM-115	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIXPR2pKSzVyPUCuNlc4OzhizszN	NGjJSZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CCRF-CEM	M1P6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmLDTWM2OD1yLkOzOVI6KM7:TR?=	MonVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
IST-SL1	NXjuSpk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWHJR\|UxRTBwM{WzOFMh\|ryP	NV\SUZNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BE-13	M3Xj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVzkfHRrUUN3ME2wMlM3PDV7IN88US=>	M1:0blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
COR-L88	MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGXXT2hKSzVyPUCuN\|Y2PCEQvF2=	MkjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
DOHH-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnXFTWM2OD1yLkSxNFI{KM7:TR?=	MlfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
A704	M1[0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX3JR\|UxRTBwNEK2O{DPxE1?	NGq1RW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KNS-81-FD	NX;Z[YNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MU\JR\|UxRTBwNESwNVch\|ryP	MnP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RPMI-8226	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4LlcWlEPTB;MD60OVY2OiEQvF2=	MmPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TGBC24TKB	M2exN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1nDfmlEPTB;MD60OVc4QCEQvF2=	NG[wS2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H1304	MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHX3fI1KSzVyPUCuOFYyPTdizszN	MkjoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MOLT-13	MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXjtZZhDUUN3ME2wMlQ3PjF\|IN88US=>	NYrwRXU4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
EW-22	NGfF[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnzkTWM2OD1yLkS2OlcyKM7:TR?=	NXj4fFV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MS-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3TlOmlEPTB;MD60Olk{OyEQvF2=	MnT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RMG-I	MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYfJR\|UxRTBwNEm0OlQh\|ryP	NFX0WHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	M33icGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NELwOHJKSzVyPUCuOVAxOTlizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1048	NW\vUm9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWTJR\|UxRTBwNUC5OVMh\|ryP	M3LQWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW1417	Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1vZZmlEPTB;MD61OVQ{QCEQvF2=	NUHjNoFvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
DB	NHvEOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn;LTWM2OD1yLkW3NFgh\|ryP	M4HwVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MEG-01	NE\hTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUXrXlJwUUN3ME2wMlU5OzJizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
EW-13	NVzSO\|NiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWrJR\|UxRTBwNUizOFEh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
LAMA-84	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXe4fJpDUUN3ME2wMlU6OjB5IN88US=>	NFrLUZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
J-RT3-T3-5	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mki4TWM2OD1yLk[wPFA5KM7:TR?=	NVXnXndHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MOLT-16	MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVzENpRNUUN3ME2wMlY2OjZ2IN88US=>	NH3HeXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
DU-4475	M3HQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX3JR\|UxRTBwNkW0Nlch\|ryP	M2joc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HAL-01	NEPvc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2rxcWlEPTB;MD63NlU1QSEQvF2=	Mke4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RD	Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUDhXIJ3UUN3ME2wMlc2QDl7IN88US=>	MlnsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
OAW-28	M4j3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHnITGdKSzVyPUCuO\|g{PyEQvF2=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HCC38	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVjZfmlZUUN3ME2wMlgxOTlizszN	NVTJT21lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NMC-G1	Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4nPSmlEPTB;MD64NVEzOSEQvF2=	M1qwSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
EW-16	M2TEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVjJR\|UxRTBwOEGzNlgh\|ryP	M2PSbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
DU-145	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHfnbIRKSzVyPUCuPFk6OjNizszN	NVvYcVJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HPAF-II	NH3aWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHjOO\|RKSzVyPUCuPVI3OjhizszN	MoC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
A427	M4K4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2jmdWlEPTB;MD65N\|AzOiEQvF2=	NFuzW\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
PA-1	M332O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVzJR\|UxRTBwOUW2OFIh\|ryP	Mk[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
OAW-42	M335[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVTNRphEUUN3ME2wMlk3OTR4IN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
L-428	NFX2PYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEX5TVNKSzVyPUGuNFEzPSEQvF2=	MmjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
COLO-824	NHy3ZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVT2[\|d7UUN3ME2xMlAyPzB6IN88US=>	NWPERVBpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
P30-OHK	NXHsSZhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{nPTGlEPTB;MT6wOFY5QCEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2170	MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NW\Nc2R1UUN3ME2xMlA3OjNizszN	Mn3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HCC2998	NXPkcHROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXjQVVZGUUN3ME2xMlA4OTN3IN88US=>	NYCzcW5GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NB14	Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1rDPGlEPTB;MT6xN\|c1QCEQvF2=	MlL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TGBC1TKB	MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnnETWM2OD1zLkG0NVUzKM7:TR?=	MmXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KP-N-YS	NFnjN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn7KTWM2OD1zLkG2NlM3KM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CAL-120	NHTQd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4TWRWlEPTB;MT6xOlQzQSEQvF2=	NI\LRoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SBC-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV7JR\|UxRTFwMUmwOVMh\|ryP	NG\FfFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
C32	NFHlWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUnkTHlwUUN3ME2xMlE6ODh6IN88US=>	NYWzPIdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HCC2157	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHTWTIZKSzVyPUGuNVk1QTRizszN	MmLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
COLO-792	M{TXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVrJR\|UxRTFwMkCwO\|Eh\|ryP	Mn\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
ES7	NIXBeVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH3iWnRKSzVyPUGuNlc6PTFizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HEL	NWXR[W5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYfrbW42UUN3ME2xMlMyODJ7IN88US=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ES4	M1;IbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MljqTWM2OD1zLkO0PVk5KM7:TR?=	NH\RR3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-SNU-1	NXvBbYRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkL5TWM2OD1zLkO2OVU2KM7:TR?=	NHH5SG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MDA-MB-415	NYrnXlZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmG4TWM2OD1zLkO4PFUh\|ryP	NI\qcI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H2342	M1jFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHXwdm9KSzVyPUGuOFAzPjlizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB69	NXPROXFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3PUTGlEPTB;MT60OlI4OSEQvF2=	NH;tPGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
D-247MG	M2\DbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{Hw[mlEPTB;MT61NVEzOiEQvF2=	MnrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SCC-4	NVXrZoRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1riNWlEPTB;MT61PVg5PyEQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HuH-7	MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmD6TWM2OD1zLk[3Nlk{KM7:TR?=	NYPlbZF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
A388	NFPZPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFHVTHZKSzVyPUGuOlg4OjRizszN	MoDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
Calu-3	NUHGUo9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkS4TWM2OD1zLkewOlk4KM7:TR?=	M3LxWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1648	M{\sdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnLGTWM2OD1zLkexOFE5KM7:TR?=	M2n1R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2052	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1PxS2lEPTB;MT63NlIxOSEQvF2=	MoTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10	MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mnv3TWM2OD1zLkezOlU3KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
DEL	NV;UZodTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXXObGkxUUN3ME2xMlc1Pjl{IN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SNU-423	NU\BPYRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGf3PXJKSzVyPUGuO\|gyPTdizszN	NGfKc5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
COR-L23	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{j2bGlEPTB;MT63PVg4PCEQvF2=	NGHBbo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OMC-1	MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MX7JR\|UxRTFwOE[wNVYh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
EW-11	MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWHJR\|UxRTFwOUW2OVch\|ryP	M{C3NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HSC-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWH0WGMyUUN3ME2xMlk3OzZ3IN88US=>	M1r1flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MLMA	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGnRT\|FKSzVyPUGuPVY3PzdizszN	NXvZclNYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
RCM-1	Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIrSdm1KSzVyPUKuNFA{QTlizszN	NVj5Wmg1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MFE-280	M2HiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1vjemlEPTB;Mj6wNlg1QCEQvF2=	NVHSTlZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ES8	M2TtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV;PbWkyUUN3ME2yMlI2PDdzIN88US=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
TE-11	NHvFXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYTJR\|UxRTJwMkm0O\|Mh\|ryP	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HuO-3N1	NFrjdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MULJR\|UxRTJwNEi3PEDPxE1?	MkDCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MHH-NB-11	NF3NUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoeyTWM2OD1{LkWxNVU5KM7:TR?=	MkT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TGBC11TKB	NEm0TlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXzT[FNuUUN3ME2yMlU4PjhzIN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HOP-92	MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{f0bmlEPTB;Mj61PFc1OyEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
IGR-1	MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFe3bnRKSzVyPUKuOlIxOzVizszN	MnPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
GOTO	NWXrXJNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYfJR\|UxRTJwNkWzO\|ch\|ryP	M4LhSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1650	M3;4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHr6WXlKSzVyPUKuO\|IzOTVizszN	Mnv3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1581	NX;4bWpHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIXhdXhKSzVyPUKuO\|k3QDFizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2405	NGTP[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXnZc3hqUUN3ME2yMlgzPzh{IN88US=>	M2jjfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
U-118-MG	NV7oVFdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4P2RWlEPTB;Mj65OlQ6OSEQvF2=	NGrlcnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
DoTc2-4510	NF3FNHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NW\Qb\|R7UUN3ME2zMlAyPDF5IN88US=>	NIHJO5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H596	NH\uW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHPRdYRKSzVyPUOuNFQ6QTdizszN	NEnqe2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MPP-89	M3S4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MW\JR\|UxRTNwMEW2OlYh\|ryP	M1riclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
GCIY	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml34TWM2OD1\|LkKwOFkyKM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW626	NFrlfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUjxV5hOUUN3ME2zMlI1PTR\|IN88US=>	NEf3clc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OCI-AML2	MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFrQZYpKSzVyPUOuN\|EzPzJizszN	Ml;UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NBsusSR	NU\6e2l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFn0ZnFKSzVyPUOuN\|Q6OzhizszN	NH\zN3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
AN3-CA	NHXPNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NULs[YN{UUN3ME2zMlQ1OjN6IN88US=>	M1joZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
EFM-19	NIXzR2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWfJR\|UxRTNwNEizN\|kh\|ryP	M4m3WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
RVH-421	NW\VNZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2DLfGlEPTB;Mz61Olg4PyEQvF2=	MnPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
5637	MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXL3bHM3UUN3ME2zMlYyOTB\|IN88US=>	NXXnRpdPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
PANC-08-13	Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4fz[mlEPTB;Mz62N\|Q4OiEQvF2=	M4KyN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
H9	NXLhcng1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH[5SYhKSzVyPUOuOlcyPDRizszN	MmHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KARPAS-299	M3LlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mlz0TWM2OD1\|Lk[3N\|YyKM7:TR?=	NHHKVGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
TE-5	NUnIWXBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn[0TWM2OD1\|LkewO\|A6KM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NOS-1	NVTnfVEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXHadFdHUUN3ME2zMlc6QDN2IN88US=>	M4HXe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HH	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MU\JR\|UxRTNwOEO4Olgh\|ryP	NG\yN4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
769-P	M3Kze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF7aUpVKSzVyPUOuPFk2OSEQvF2=	NGfZO5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CHP-212	NGS4ZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWniSmROUUN3ME2zMlkzPTR7IN88US=>	MmnwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H82	Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2PuXGlEPTB;Mz65OVk{PiEQvF2=	MoTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
Mo-T	Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXy5PIZlUUN3ME20MlA1OzF{IN88US=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
BB65-RCC	NF32fo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmG5TWM2OD12LkC0N\|k6KM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW1990	M{nZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1fZdmlEPTB;ND6wOVkxQCEQvF2=	NULUdphmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
LK-2	NEGx[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlLITWM2OD12LkGxNlk{KM7:TR?=	MmO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
ES5	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX3JR\|UxRTRwMUO5PFUh\|ryP	MlLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
JVM-3	NIjXbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIDY[lZKSzVyPUSuNVgzOjJizszN	M4f3bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
RPMI-7951	NHiyb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWf0W5JmUUN3ME20MlIzPDF\|IN88US=>	MmPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
Calu-6	M3HJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUHJR\|UxRTRwMke4PFEh\|ryP	Mki4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LC-2-ad	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnG3TWM2OD12LkK5OVY5KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW954	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGS5Z5BKSzVyPUSuNlk3PiEQvF2=	MkDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
H-EMC-SS	NWnhfpFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1vkXmlEPTB;ND6zNVg{OSEQvF2=	NVy1b5ZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ES3	NYPVT3R7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUfrfGxDUUN3ME20MlM2PDRzIN88US=>	NGDQNlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
no-11	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXvBV2tKUUN3ME20MlM2PTV2IN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
LAN-6	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml6yTWM2OD12LkS1NVg6KM7:TR?=	M3KwcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
FTC-133	NYG5c5VjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MojRTWM2OD12LkWzPVUh\|ryP	NVnNRpE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
8505C	NU[wfG1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnTJTWM2OD12LkW0NlMh\|ryP	NXvQc3hqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW620	NFjLN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1LzXGlEPTB;ND61O\|A2PyEQvF2=	MnfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
BCPAP	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2rIemlEPTB;ND62N\|Q5OSEQvF2=	NHftboo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SK-LU-1	M2TYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVLmSoFUUUN3ME20MlY3ODh7IN88US=>	MorDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1623	M{XLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1f5SWlEPTB;ND63NFIzQCEQvF2=	NXrEWW83RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
C2BBe1	MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVO3fI5zUUN3ME20Mlc1ODB6IN88US=>	M2jDN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
GP5d	NH7uN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEXQNIxKSzVyPUSuO\|g{QDhizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB6	MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1zDS2lEPTB;ND64OlIxPCEQvF2=	NFTGT4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MDA-MB-157	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M12xOGlEPTB;ND64PFc3KM7:TR?=	NInDW2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
UMC-11	NYLTe29pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHzlWppKSzVyPUSuPFg6PjRizszN	M{D4elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HCC1419	MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlLDTWM2OD12LkmwNFY{KM7:TR?=	M{fyd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2029	M16yV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX:4SHJzUUN3ME20Mlk1OTh3IN88US=>	M2LKZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LXF-289	NVfMXGU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEDSUIRKSzVyPUWuNFM4OTlizszN	M{HTc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KINGS-1	NWLLO2xkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1qxTWlEPTB;NT6wO\|c1PCEQvF2=	NFrzW3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HD-MY-Z	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1TPOGlEPTB;NT6yN\|k3QSEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ESS-1	Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnT1TWM2OD13LkK1OVk4KM7:TR?=	M{jTWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
GI-1	M3W0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnLvTWM2OD13LkK3PVI3KM7:TR?=	NGnO[os9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
RPMI-2650	NFTwbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV\JR\|UxRTVwM{[xOkDPxE1?	NILjNWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
IA-LM	MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGTjZ\|lKSzVyPUWuN\|k5PzFizszN	NYLhdWZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KP-4	NEnHRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWnGW48{UUN3ME21MlQ3OzN2IN88US=>	M2Tp[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
G-402	NFvueItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1W3d2lEPTB;NT61NVg3PSEQvF2=	NXu3TXlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
OS-RC-2	NX\PfpBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NILxUXZKSzVyPUWuOVI3ODRizszN	NYrTe406RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H1155	MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWfPZmo1UUN3ME21MlU1QTV3IN88US=>	NEjxcFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OE19	NUfheGx2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHrwWYFKSzVyPUWuOlg3OjRizszN	MnfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
U-2-OS	NYXJeYxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{fCUmlEPTB;NT64PVAyOyEQvF2=	MkKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SCC-15	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGjIdpJKSzVyPUWuPVM3PjJizszN	NXrVfoZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H630	NWjl[YU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHPjZYhKSzVyPUWuPVk1ODRizszN	NWiwb\|NZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
PFSK-1	MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4rZW2lEPTB;Nj6wOVI2QSEQvF2=	Mn;iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1770	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1HxeGlEPTB;Nj6yNFg4PCEQvF2=	MliyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-3	NV[wcnB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH;TfmVKSzVyPU[uOFI6OTVizszN	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
LB1047-RCC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVr2OpA4UUN3ME22MlQ4PjJ3IN88US=>	NWS2bpRmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H446	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWDJR\|UxRTZwNkK5NlUh\|ryP	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW780	NXj0SWpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYTWUGNoUUN3ME22MlcxOTh3IN88US=>	M4m0RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NEC8	NEnGbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGPmNmxKSzVyPU[uO\|Y3OyEQvF2=	M1nFZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NOMO-1	M{HZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFvYbHhKSzVyPU[uO\|gyOTFizszN	NYXweoE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
COLO-668	NV\MNHZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIXXTlFKSzVyPU[uPFQ{QDdizszN	M2DiNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MC116	MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF3Q[5pKSzVyPU[uPVM5QTdizszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HCC1937	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2PhTGlEPTB;Nj65PVI2OSEQvF2=	M17hVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-N87	NUi0bGFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEC1T4VKSzVyPUeuNVkzQTNizszN	NUDrdFlnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
COLO-320-HSR	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NInpTo5KSzVyPUeuNlI4OzhizszN	NFPQfXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HCC1806	M1\RZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH3IfYhKSzVyPUeuNlYxPDRizszN	M332XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
OVCAR-3	M{fmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkL1TWM2OD15LkOzNFM5KM7:TR?=	MnzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NUGC-3	MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV[zO4t2UUN3ME23MlM6Pjl2IN88US=>	NYLUOmptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW1783	M4TUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{PNb2lEPTB;Nz60N\|E4PSEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
GCT	NW\3RVZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHLoemZKSzVyPUeuOVY6ODZizszN	NV3ZZ2I1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H2126	NXHuSY1{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkKxTWM2OD15LkezOlI2KM7:TR?=	NGPkb2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MEL-HO	M1XuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1HldWlEPTB;Nz63O\|A2PCEQvF2=	M1XUPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
CAPAN-1	Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MX3JR\|UxRTdwN{ezOVch\|ryP	NGXycno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW756	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1;NfGlEPTB;Nz63PFM{OyEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SKG-IIIa	NGrL[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M17nOWlEPTB;Nz64NVg6OiEQvF2=	M{nWc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HCE-T	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWDJR\|UxRTdwOEe3PFMh\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
Ca-Ski	M4\QUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlzMTWM2OD15Lkm5N\|g{KM7:TR?=	M3vnNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
COLO-684	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlzVTWM2OD16LkCxPFE5KM7:TR?=	Mmq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KYSE-70	M37INGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4HZ[mlEPTB;OD6wO\|czQSEQvF2=	M2mwdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
TI-73	Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NELC[VVKSzVyPUiuNlU5PTFizszN	NH\MSWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
BT-20	NVXmfpJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFPWN2RKSzVyPUiuNlYxPTJizszN	NIK4ZYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MHH-ES-1	MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX\YcWp4UUN3ME24MlUyQDN2IN88US=>	NWXnelF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
TE-12	M2HaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFTzUZVKSzVyPUiuOVk6OzFizszN	M2e2V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
YH-13	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mk\STWM2OD16Lk[xNFA5KM7:TR?=	M3fNXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SF126	M4TuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlvBTWM2OD16LkizPFY2KM7:TR?=	M2PGbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
J82	M1vDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MojKTWM2OD16LkmwNFM5KM7:TR?=	MlTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RCC10RGB	NGP2V5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mlj1TWM2OD16Lkm5OVYyKM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SK-UT-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGTZfmZKSzVyPUmuNFQ6PDVizszN	NYnpbHRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
LB2241-RCC	NVLLPFExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWnJR\|UxRTlwMUmxN\|ch\|ryP	NIrrXW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LB996-RCC	M{jlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnHZTWM2OD17LkG5PFkh\|ryP	MkT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EPLC-272H	M2O0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mlm4TWM2OD17LkO3OlU4KM7:TR?=	MlrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
CTV-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlraTWM2OD17LkW2OVMzKM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HSC-2	M4jCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoT1TWM2OD17LkW3OVUh\|ryP	NW[xc5QxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SK-MEL-28	M1fDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NE\hSo5KSzVyPUmuOlE5QTNizszN	M1L6[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MMAC-SF	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUXJR\|UxRTlwNki3OUDPxE1?	MmPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
CP50-MEL-B	NEnjemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MW\JR\|UxRTlwN{W3PFIh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HT-1080	M{Sxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3K2cmlEPTB;OT63O\|c{QSEQvF2=	NIO2VWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HEC-1	NFmydZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYrJR\|UxRTFyLkOzOVIh\|ryP	MoLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
AGS	NIHlUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXPEWGhXUUN3ME2xNE4{PzRizszN	M1PZXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
GAMG	MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUHJR\|UxRTFyLkWxOlIh\|ryP	M1jHclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW48	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX\qSVZoUUN3ME2xNE42OTh7IN88US=>	Mnu3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
U031	M1PUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUPJR\|UxRTFyLkW5NFgh\|ryP	NF;CPVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OVCAR-5	NFXVV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWW2boR7UUN3ME2xNE43PDJ7IN88US=>	M1P3T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SF295	M1jnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHrrO4pKSzVyPUGwMlY4ODRizszN	NGH0SI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
BHT-101	M{S1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUXwOpZZUUN3ME2xNE44OTd5IN88US=>	M{\yRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
VMRC-RCZ	NVqzWWhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH:1bGlKSzVyPUGxMlMzODFizszN	M4K4N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ACHN	M1fmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4HKcmlEPTB;MUGuOFIyOSEQvF2=	MknmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H526	NFHTfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUXJR\|UxRTFzLkWwOFMh\|ryP	M4jtNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MN-60	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYTFbWkzUUN3ME2xNU42OzlizszN	NIHj[5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H2291	NXezUW5tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4LwTGlEPTB;MUGuOVQ3PiEQvF2=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SCC-25	NVSycXY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn3oTWM2OD1zMT63OVU3KM7:TR?=	NF3zPGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SK-MEL-2	M3S4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVjRdYw6UUN3ME2xNU44PjN5IN88US=>	NG\jN209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SN12C	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXPJR\|UxRTFzLkmzOVUh\|ryP	M{DhUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H69	M1Lvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHfqb5pKSzVyPUGyMlQzOzRizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ME-180	MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mk\JTWM2OD1zMj63NFU1KM7:TR?=	NHOxTJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MC-IXC	M2LHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXPJR\|UxRTF{Lke1NVgh\|ryP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2347	NH;5VmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHziTY1KSzVyPUGyMlc3OTRizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
M059J	NXHn[Yp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3jmSmlEPTB;MUKuO\|czPyEQvF2=	NYLTXG9tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
A2058	NFr4RWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M33XV2lEPTB;MUKuPFY5OSEQvF2=	NUGxfJRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
VA-ES-BJ	MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXj5[XFxUUN3ME2xNk45Pzh3IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
Ca9-22	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MU\JR\|UxRTF{Lkm0OVEh\|ryP	NXrSOVhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KNS-42	M3nld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXzJR\|UxRTF{Lkm5PFQh\|ryP	MonkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LoVo	MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV;JR\|UxRTF\|LkKzNVMh\|ryP	NHnzNGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
AM-38	NUfPVmlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml3GTWM2OD1zMz6yOVY3KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB5	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHrnVHFKSzVyPUGzMlM4PTJizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
L-363	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4LkTmlEPTB;MUOuOFA{OyEQvF2=	MlzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-30	M4jHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVTJR\|UxRTF2LkC2OFUh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1563	NHrZOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXjJR\|UxRTF2Lk[wN\|kh\|ryP	NHLmWZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H2228	M4HGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUHJR\|UxRTF2Lk[wO\|ch\|ryP	MmDwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MFM-223	M2POcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXrJR\|UxRTF3LkG4NVMh\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
LB831-BLC	NGPrdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVPJR\|UxRTF3LkK3Olch\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW872	NH3XUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEHSeYlKSzVyPUG1MlMxQDZizszN	NVTsNYdFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H522	NGHCXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MY\JR\|UxRTF3LkOzNFYh\|ryP	Mk\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EW-1	NY\VZmk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUn1V4VjUUN3ME2xOU42PDZ{IN88US=>	M3PNZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HN	M4jSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHXJbW9KSzVyPUG1MlU6PDJizszN	M4e1W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW837	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3vUTGlEPTB;MUWuO\|g1PyEQvF2=	NYXBdYJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SCC-9	Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFfiN5pKSzVyPUG1MlgyOTRizszN	Ml7vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MKN7	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXvPe3Y2UUN3ME2xOU46PzN{IN88US=>	M33WV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KYSE-410	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWDJR\|UxRTF4LkW5NUDPxE1?	NEL5SnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SK-N-DZ	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHH5R3FKSzVyPUG2MlYyOTZizszN	NIH1XI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
COR-L105	Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NI[5fmZKSzVyPUG2MlY2OjhizszN	Mlr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LB2518-MEL	NYjsbI1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGfmRYdKSzVyPUG2Mlg{QDlizszN	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OVCAR-4	NE\x[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXvJR\|UxRTF4Lki4OlIh\|ryP	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
TK10	NWHZRoV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHTtSW1KSzVyPUG2Mlk1PzNizszN	NUC5[YhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KNS-62	NEjoNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NI\nbXdKSzVyPUG2Mlk4PzdizszN	NGHtRXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
RPMI-8866	NF7XWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXXJR\|UxRTF5LkG3N\|Ih\|ryP	NYizcFdPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HuP-T4	NYGwV4NTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmPCTWM2OD1zNz6yOFk2KM7:TR?=	M2X4S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
CGTH-W-1	NFzK[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnTWTWM2OD1zNz61NlE6KM7:TR?=	NVH4cIdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
T-24	NEnvUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{ft[WlEPTB;MUeuOVM1PyEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HT-3	NIXtWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MW\JR\|UxRTF5LkW5NVQh\|ryP	Mn75QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KS-1	M{KwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnPRTWM2OD1zNz62O\|Mh\|ryP	NFnPXVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H1792	M1XNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlHWTWM2OD1zNz63PVgh\|ryP	NIXyO2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ABC-1	MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHPM[G9KSzVyPUG3MlgyPDFizszN	NV\qbGVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BPH-1	M124VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGj0XmhKSzVyPUG4MlE3QDVizszN	NHv6OlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
A431	NYH4XJp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnTJTWM2OD1zOD60NVI4KM7:TR?=	MkjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
T98G	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmnBTWM2OD1zOD61NVU4KM7:TR?=	M3K0[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
BHY	M3vTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUP4TZhqUUN3ME2xPE45PjlizszN	NIDSW449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
Capan-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHS2SIlKSzVyPUG4MlkxPzhizszN	MmnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MDA-MB-175-VII	M4TnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXL4PW9WUUN3ME2xPE46OjB7IN88US=>	NImySY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CAL-27	NIezToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX;JR\|UxRTF7LkC0PFch\|ryP	NHPCXmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
AsPC-1	MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH30UlBKSzVyPUG5Mlg3PTdizszN	MmGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KU812	NFXBfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH;hdHhKSzVyPUG5Mlk2PzNizszN	MlnBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H441	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{TUeGlEPTB;MkCuNFAyKM7:TR?=	MlLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
Mewo	NF;OeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mk\ZTWM2OD1{MD6xNlg5KM7:TR?=	MkTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-24	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1HzSWlEPTB;MkCuNVQ4PyEQvF2=	NH35PVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H727	NXnXWHZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYDJR\|UxRTJyLkK3NFQh\|ryP	NUmwNGRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
EKVX	M4DBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWrJR\|UxRTJyLk[wOkDPxE1?	MoL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RT-112	M2e1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFzsbXZKSzVyPUKwMlYyOjJizszN	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CAMA-1	MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MonPTWM2OD1{MD65PFA{KM7:TR?=	M2f2SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW900	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHOwTlBKSzVyPUKxMlAyPDlizszN	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H23	NUHoOmNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVm4bIQ1UUN3ME2yNU4yOjd5IN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SK-PN-DW	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUK5XHNuUUN3ME2yNU4yPjR7IN88US=>	NYHQTYN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BB30-HNC	NUjCRVRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1jmS2lEPTB;MkGuNlc1PSEQvF2=	M4iwe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
VM-CUB-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M13hUWlEPTB;MkGuN\|U{PiEQvF2=	MlHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
IST-MEL1	NUeze5F3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml;BTWM2OD1{MT6zOlkzKM7:TR?=	NWeyZ41PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CTB-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1zHZWlEPTB;MkGuOFc2PSEQvF2=	NYDBU\|JGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
LCLC-103H	NFPPdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHfFc5hKSzVyPUKyMlE2QDJizszN	M3HxTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
PANC-03-27	NWHFSWhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmftTWM2OD1{Mj61NVY6KM7:TR?=	MnHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HTC-C3	NFPxb\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MU\JR\|UxRTJ{LkW1OVUh\|ryP	MoL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TE-8	NWK2WGoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWfJR\|UxRTJ\|LkK1OlUh\|ryP	NHvxWYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H292	NHXHXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYPJR\|UxRTJ3LkO1N\|Yh\|ryP	M3jLTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
COLO-680N	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlvSTWM2OD1{NT62N\|I6KM7:TR?=	M3\yWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KYSE-520	NHLSXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVPJR\|UxRTJ3Lk[0OEDPxE1?	NYXCbXBJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NB10	MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml7DTWM2OD1{Nj6zNVE4KM7:TR?=	Mor6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H661	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFnrPGVKSzVyPUK2MlQ4OTNizszN	NEPsXVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
GMS-10	M{\FfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NG\xTmdKSzVyPUK2Mlg3OzhizszN	M1fuXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2122	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4S1S2lEPTB;Mk[uPVk6QCEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OVCAR-8	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnrFTWM2OD1{Nz6wOlM5KM7:TR?=	NX2xT5IzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
DJM-1	NVK2TVVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVvJR\|UxRTJ5LkG0OVQh\|ryP	MlS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
UACC-893	MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{nwR2lEPTB;MkeuPVg4QCEQvF2=	MlLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
C8166	NGHXTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4\4bWlEPTB;MkiuOlk{QCEQvF2=	NHvHPFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H1693	MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmTnTWM2OD1{OD62PVc2KM7:TR?=	M2r2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
TYK-nu	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUG5d2hoUUN3ME2zNE4xOzR3IN88US=>	NIj6OFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW1710	MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWHJR\|UxRTNyLkGyOkDPxE1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
A375	M2ThUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGTpUGlKSzVyPUOwMlMzPDNizszN	NYPUWlZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HMV-II	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1L1bmlEPTB;M{GuN\|U6OiEQvF2=	NVmwV21bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H2087	NWXXeG8xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFjHUIFKSzVyPUOxMlY{PTJizszN	MnXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
CAL-54	NE\yfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFj2clRKSzVyPUOxMlczPDFizszN	Mli5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HCC70	NXfwNWhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mle4TWM2OD1\|Mj6xN\|g4KM7:TR?=	NWTHenRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ES1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4m1eGlEPTB;M{KuN\|A3OiEQvF2=	MkPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1355	M2XIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGT5UW1KSzVyPUOzMlIxPCEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CFPAC-1	M3fnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXfJR\|UxRTN\|LkKzN\|Ih\|ryP	NEHDW209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MKN28	MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV;CNnlGUUN3ME2zN{4{QDB7IN88US=>	NHn4XVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HDLM-2	M1HXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUjqNGU2UUN3ME2zN{43QTNzIN88US=>	M33ySlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
PANC-10-05	NEe2fVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVvqb\|ZWUUN3ME2zOE4yODF2IN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SAS	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXfkWWJGUUN3ME2zOE41PTZ3IN88US=>	MlfBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HCC1395	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2fvUGlEPTB;M{SuO\|E5PiEQvF2=	NG\ReZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
8305C	MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYntVmZ3UUN3ME2zOU45PDF3IN88US=>	M1fhXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KM12	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2fmXmlEPTB;M{[uO\|U1PyEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW1116	M4HtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX3JR\|UxRTN5LkW5PVIh\|ryP	NW\NO3lERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SK-MEL-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFXpWYRKSzVyPUO4MlM{QDlizszN	NV;TUmt6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HCC2218	M{fpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFfKbJpKSzVyPUO4MlY2OTlizszN	NV7IUlY3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
T84	M{W2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoHyTWM2OD1\|OD63OFA6KM7:TR?=	M{LWSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ETK-1	NYfoTYNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3K5SWlEPTB;M{muNFIzKM7:TR?=	M2HETVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
COLO-800	NXK5T3FrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3XJ[GlEPTB;M{muN\|g3QCEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CAL-12T	NHPVNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{PON2lEPTB;M{muOVI5OSEQvF2=	M4\CblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ACN	Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mmm0TWM2OD12MD60PVEyKM7:TR?=	NWi3T45KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SJSA-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlPnTWM2OD12MT6xOVk3KM7:TR?=	M3naZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
PSN1	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoHyTWM2OD12MT6xO\|Q6KM7:TR?=	NFrHTm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
D-566MG	NYP4XWdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWPJR\|UxRTRzLkKwPFYh\|ryP	NUXLTZo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
EGI-1	NHWzfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWnJR\|UxRTR{LkSyPEDPxE1?	NHHme2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
A204	M3Lh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NW\Db2dUUUN3ME20Nk43Ozh6IN88US=>	NU\kToF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
Saos-2	MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2\mUmlEPTB;NEKuPFM3QSEQvF2=	NHvw[I49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SNU-C2B	M4HUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnS0TWM2OD12Mz62PFc5KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HLE	M2D2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWrVZoVDUUN3ME20OE4xQDV4IN88US=>	NYj2WZN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW1463	M{DtTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYTBWmhmUUN3ME20OE46QTdzIN88US=>	M2Xmc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
DSH1	NUf5cnQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYrJR\|UxRTR3LkCwN\|Mh\|ryP	NEHNRW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MCF7	M3myU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4fHb2lEPTB;NEWuOVA2OSEQvF2=	Mo\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
K5	NV\MZnJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mly3TWM2OD12NT65OFA2KM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H358	M4LvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mk\vTWM2OD12Nz6yNVUh\|ryP	MojJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H2030	NXnpWVBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYnJR\|UxRTR5LkKzO\|Qh\|ryP	M{D5W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW948	M1vye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mo[1TWM2OD12Nz60OlQh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
BALL-1	M{i4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXjuVJRpUUN3ME20O{43OTZ6IN88US=>	NYq1fJBTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
TE-9	NHvl[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHH1NW9KSzVyPUS3Mlk2QDFizszN	MoiwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SK-N-FI	M3zKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1jIdWlEPTB;NEiuNFM2QCEQvF2=	MlfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KALS-1	NVzWcmYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4fzTWlEPTB;NEiuNVI5QSEQvF2=	NGPaVIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HO-1-N-1	NVLCTGNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmPoTWM2OD12OD63OFQ2KM7:TR?=	NXO4Z4dNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H2452	M3LhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEHMTYNKSzVyPUS5MlEyPTJizszN	MnnQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
OC-314	NUfGVm1KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3HiNGlEPTB;NEmuOlg{PCEQvF2=	Mk\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

In vivo

When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. ^[2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. ^[2]

Protocol

Kinase Assay: ^[1]	- Collapse Affinity determination: Binding affinities (K_i or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research: ^[1]	- Collapse Cell lines: SCLC cell lines Concentrations: 0-1 μM Incubation Time: 48 hours Method: Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO₂. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 ⁴) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice Dosages: 100 mg/kg/d Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Navitoclax (ABT-263) SDF

Molecular Weight	974.61
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
CAS No.	923564-51-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
Answer:
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
Question 2:
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
Answer:
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Venetoclax (ABT-199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax (BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
(R)-(-)-Gossypol acetic acid

(R)-(-)-Gossypol (AT-101) acetic acid, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. AT-101 simultaneously triggers apoptosis and a cytoprotective type of autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)